Find Clinical Trials & Studies

Scleroderma Phase II study evaluating rapcabtagene autoleucel in participants with diffuse cutaneous systemic sclerosis

I'm Interested!
Please call
1-833-78TRIAL

A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis

  • Sex: Any
  • Age: Adult (18 - 64)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase II
  • Conditions Being Studied:

Study Purpose

The purpose of this study is to evaluate if i.v. rapcabtagene autoleucel (administered once following lymphodepletion) is safe and effective in participants with severe refractory diffuse cutaneous systemic sclerosis.

Who Can Participate

Age: 18-65 years old

Principal Investigator
Marina Magrey MD
Department/Division
Medicine (Rheumatology)
  • UH IRB: SITE00002502
  • StudyID: 2025-01714
  • ClinicalTrials.gov: N/A
I'm Interested!
Please call
1-833-78TRIAL

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL

Cancer Trials: 1-866-373-1464